1. Scrip
  2. >>Business

Novo Nordisk Enjoys Obesity Sales Boost Despite Wegovy Supply Issues

Reports 82% Growth In Q3

 
• By Ayisha Sharma

Novo Nordisk’s obesity product sales have soared against the odds as supply chain issues for recently approved Wegovy continued.  

Novo Nordisk A/S is continuing to enjoy strong growth for its obesity franchise but the contribution of its newest product Wegovy remains unclear after the drug experienced supply chain issues following US approval and launch in June.

Overall, the diabetes-focused firm reported net profits of DKK12.1bn in the third quarter, with total sales climbing by 15% (CER) to DKK35.6bn ($5.6bn)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

 
• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.